Pentoxifylline for intermittent claudication

Published on Sep 29, 2015in Cochrane Database of Systematic Reviews7.89
· DOI :10.1002/14651858.CD005262.PUB3
Kareem Salhiyyah5
Estimated H-index: 5
Rachel Forster8
Estimated H-index: 8
(Edin.: University of Edinburgh)
+ 3 AuthorsJonathan Michaels33
Estimated H-index: 33
(University of Sheffield)
BACKGROUND: Intermittent claudication (IC) is a symptom of peripheral arterial disease (PAD) and is associated with high morbidity and mortality. Pentoxifylline, one of many drugs used to treat IC, acts by decreasing blood viscosity, improving erythrocyte flexibility and promoting microcirculatory flow and tissue oxygen concentration. Many studies have evaluated the efficacy of pentoxifylline in treating individuals with PAD, but results of these studies are variable. This is an update of a review first published in 2012. OBJECTIVES: To determine the efficacy of pentoxifylline in improving the walking capacity (i.e. pain-free walking distance and total (absolute, maximum) walking distance) of individuals with stable intermittent claudication, Fontaine stage II. SEARCH METHODS: For this update, the Cochrane Vascular Group Trials Search Co-ordinator searched the Specialised Register (last searched April 2015) and the Cochrane Register of Studies (2015, Issue 3). SELECTION CRITERIA: All double-blind, randomised controlled trials (RCTs) comparing pentoxifylline versus placebo or any other pharmacological intervention in patients with IC Fontaine stage II. DATA COLLECTION AND ANALYSIS: Two review authors separately assessed included studies,. matched data and resolved disagreements by discussion. Review authors assessed the methodological quality of studies by using the Cochrane 'Risk of bias' tool and collected results related to pain-free walking distance (PFWD) and total walking distance (TWD). Comparison of studies was based on duration and dose of pentoxifylline. MAIN RESULTS: We included in this review 24 studies with 3377 participants. Seventeen studies compared pentoxifylline versus placebo. In the seven remaining studies, pentoxifylline was compared with flunarizine (one study), aspirin (one study), Gingko biloba extract (one study), nylidrin hydrochloride (one study), prostaglandin E1 (two studies) and buflomedil and nifedipine (one study). The quality of the evidence was generally low, with large variability in reported findings.. Most included studies did not report on random sequence generation and allocation concealment, did not provide adequate information to allow selective reporting to be judged and did not report blinding of assessors. Heterogeneity between included studies was considerable with regards to multiple variables, including duration of treatment, dose of pentoxifylline, baseline walking distance and participant characteristics; therefore, pooled analysis was not possible.Of 17 studies comparing pentoxifylline with placebo, 14 reported TWD and 11 reported PFWD; the difference in percentage improvement in TWD for pentoxifylline over placebo ranged from 1.2% to 155.9%, and in PFWD from -33.8% to 73.9%. Testing the statistical significance of these results generally was not possible because data were insufficient. Most included studies suggested improvement in PFWD and TWD for pentoxifylline over placebo and other treatments, but the statistical and clinical significance of findings from individual trials is unclear. Pentoxifylline generally was well tolerated; the most commonly reported side effects consisted of gastrointestinal symptoms such as nausea. AUTHORS' CONCLUSIONS: Given the generally poor quality of published studies and the large degree of heterogeneity evident in interventions and in results, the overall benefit of pentoxifylline for patients with Fontaine class II intermittent claudication remains uncertain. Pentoxifylline was shown to be generally well tolerated.Based on total available evidence, high-quality data are currently insufficient to reveal the benefits of pentoxifylline for intermittent claudication.
Figures & Tables
📖 Papers frequently viewed together
603 Citations
12 Authors (Alan T. Hirsch, ..., William R. Hiatt)
3,212 Citations
10.5k Citations
#1Risha Lane (Hull Royal Infirmary)H-Index: 2
#2Amy E. Harwood (Hull Royal Infirmary)H-Index: 10
Last. Gillian Leng (National Institute for Health and Care Excellence)H-Index: 27
view all 4 authors...
Background Exercise programmes are a relatively inexpensive, low-risk option compared with other more invasive therapies for leg pain on walking (intermittent claudication (IC)). This is an update of a review first published in 1998. Objectives The prime objective of this review was to determine whether an exercise programme in people with intermittent claudication was effective in alleviating symptoms and increasing walking treadmill distances and walking times. Secondary objectives were to det...
603 CitationsSource
Abstract. Background: The aim of this study was to compare the simultaneous double-protection method (proximal balloon plus distal filter) with distal-filter protection or proximal-balloon protection alone in asymptomatic patients during carotid artery stenting. Patients and methods: 119 consecutive patients were investigated for carotid artery stentings in the extracranial internal carotid artery with the use of distal filters (n = 41, 34.4 %), proximal balloon (MoMa) protection (n = 40, 33.6 %...
6 CitationsSource
#1Rachel Bedenis (Edin.: University of Edinburgh)H-Index: 4
#2Marlene C. W. Stewart (Edin.: University of Edinburgh)H-Index: 20
Last. Gerard Stansby (Freeman Hospital)H-Index: 39
view all 6 authors...
Background Peripheral arterial disease (PAD) affects between 4% and 12% of people aged 55 to 70 years, and 20% of people over 70 years. A common complaint is intermittent claudication, characterised by pain in the legs or buttocks that occurs with exercise and which subsides with rest. Compared with age-matched controls, people with intermittent claudication have a three- to six-fold increase in cardiovascular mortality. Symptoms of intermittent claudication, walking distance, and quality of lif...
76 CitationsSource
#1Yang Meng (University of Sheffield)H-Index: 17
#2Hazel Squires (University of Sheffield)H-Index: 15
Last. Mark E. O'DonnellH-Index: 20
view all 9 authors...
We assessed the cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for intermittent claudication due to peripheral arterial disease (PAD) in adults whose symptoms continue despite a period of conventional management. A Markov decision model was developed to assess the lifetime costs and benefits of each vasoactive drug compared to no vasoactive drug and with each other. Regression analysis was undertaken to model the relationship between maximum walking distance and util...
11 CitationsSource
#1F. Gerald R. Fowkes (Edin.: University of Edinburgh)H-Index: 46
#2Diana Rudan (Edin.: University of Edinburgh)H-Index: 11
Last. Michael H. Criqui (UCSD: University of California, San Diego)H-Index: 152
view all 11 authors...
Summary Background Lower extremity peripheral artery disease is the third leading cause of atherosclerotic cardiovascular morbidity, following coronary artery disease and stroke. This study provides the first comparison of the prevalence of peripheral artery disease between high-income countries (HIC) and low-income or middle-income countries (LMIC), establishes the primary risk factors for peripheral artery disease in these settings, and estimates the number of people living with peripheral art...
1,585 CitationsSource
#1Miranda W. Langendam (UvA: University of Amsterdam)H-Index: 33
#2Elie A. Akl (AUB: American University of Beirut)H-Index: 96
Last. Holger J. Schünemann (McMaster University)H-Index: 155
view all 6 authors...
Cochrane Reviews are intended to help providers, practitioners and patients make informed decisions about health care. The goal of the Cochrane Applicability and Recommendation Methods Group (ARMG) is to develop approaches, strategies and guidance that facilitate the uptake of information from Cochrane Reviews and their use by a wide audience with specific focus on developers of recommendations and on healthcare decision makers. This paper is part of a series highlighting developments in systema...
134 CitationsSource
#1Lindsay Robertson (Edin.: University of Edinburgh)H-Index: 22
#1Lindsay Robertson (Edin.: University of Edinburgh)H-Index: 15
Last. Alina Andras (Freeman Hospital)H-Index: 11
view all 2 authors...
Background Peripheral arterial disease (PAD) is a common cause of morbidity in the general population. While numerous studies have established the efficacy of prostanoids in PAD stages III and IV, the question of the role of prostanoids as an alternative or additive treatment in patients suffering from intermittent claudication (PAD II) has not yet been clearly answered. This is an update of a Cochrane Review first published in 2004. Objectives To determine the effects of prostanoids in patients...
15 CitationsSource
#1Tine De Backer (Ghent University Hospital)H-Index: 20
#2Robert Vander Stichele (UGent: Ghent University)H-Index: 41
Background Intermittent claudication (IC) is pain caused by chronic occlusive arterial disease, that develops in a limb during exercise and is relieved with rest. Buflomedil is a vasoactive agent used to treat peripheral vascular disease. However, its clinical efficacy for IC has not yet been critically examined. Objectives To evaluate the available evidence on the efficacy of buflomedil for IC. Search strategy We searched the specialized trials register of the Cochrane Peripheral Vascular Disea...
33 CitationsSource
#1Jpt HigginsH-Index: 1
#2S. R. GreenH-Index: 1
Last. Julian P T HigginsH-Index: 135
view all 3 authors...
4,699 Citations
#1Tine De Backer (UGent: Ghent University)H-Index: 20
#2Robert Vander Stichele (UGent: Ghent University)H-Index: 41
Last. Luc M. Van Bortel (UGent: Ghent University)H-Index: 58
view all 4 authors...
Background : Lifestyle changes and cardiovascular prevention measures are a primary treatment for intermittent claudication (IC). Symptomatic treatment with vasoactive agents (Anatomic Therapeutic Chemical Classification (ATC) for medicines from the World Health Organisation class CO4A) is controversial. Objectives : To evaluate evidence on the efficacy and safety of oral naftidrofuryl (ATC CO4 21) versus placebo on the pain-free walking distance (PFWD) of people with IC by using a meta-analysis...
42 CitationsSource
Cited By48
#1Ahmed Ismaeel (Baylor University)H-Index: 6
#2K. Leigh Greathouse (Baylor University)H-Index: 8
Last. Robert J Widmer (Scott & White Hospital)H-Index: 8
view all 0 authors...
Peripheral artery disease (PAD) affects over 200 million people worldwide, resulting in significant morbidity and mortality, yet treatment options remain limited. Among the manifestations of PAD is a severe functional disability and decline, which is thought to be the result of different pathophysiological mechanisms including oxidative stress, skeletal muscle pathology, and reduced nitric oxide bioavailability. Thus, compounds that target these mechanisms may have a therapeutic effect on walkin...
#1Tamar S. Polonsky (U of C: University of Chicago)H-Index: 22
#2Mary M. McDermott (NU: Northwestern University)H-Index: 90
Importance Lower extremity peripheral artery disease (PAD) affects approximately 8.5 million people in the US and approximately 230 million worldwide. Observations Peripheral artery disease is uncommon before aged 50 years but affects up to 20% of people aged 80 years and older. It can be noninvasively diagnosed with the ankle-brachial index (ABI), a ratio of Doppler-recorded pressures in the dorsalis pedis and/or posterior tibial artery in each leg to brachial artery pressures. An ABI value les...
#1Henrik Hoel (University of Oslo)H-Index: 4
#2Erik Mulder Pettersen (NTNU: Norwegian University of Science and Technology)H-Index: 1
Last. Jonny Hisdal (University of Oslo)H-Index: 20
view all 6 authors...
Abstract Objective We investigated the effects of lower extremity intermittent negative pressure (INP) treatment for 1 hour two times daily for 12 weeks on the walking distance of patients with intermittent claudication (IC). Methods Patients with IC were randomized to treatment with −40 mm Hg INP (treatment group) or −10 mm Hg INP (sham control group). Pain-free walking distance (PWD) and maximal walking distance (MWD) on a treadmill, resting and postexercise ankle-brachial index, resting and p...
2 CitationsSource
#1Kristen J. BubbH-Index: 17
#2Dhanya RavindranH-Index: 3
Last. Gemma A. FigtreeH-Index: 31
view all 10 authors...
Aims/Hypothesis: Peripheral arterial disease (PAD) is a major burden, resulting in limb claudication, repeated surgical interventions and amputation. There is an unmet need for improved medical management of PAD that improves quality of life, maintains activities of daily life and reduces complications. Nitric oxide (NO)/redox balance is a key regulator of angiogenesis. We have previously shown beneficial effects of a β3 adrenergic receptor (β3AR) agonist on NO/redox balance. We hypothesized tha...
#1Samar H. Gerges (Ain Shams University)H-Index: 3
#2Sara A. Wahdan (Ain Shams University)H-Index: 4
Last. Ebtehal El-Demerdash (Ain Shams University)H-Index: 26
view all 4 authors...
Abstract Non-alcoholic fatty liver disease (NAFLD) is a disorder of excessive fat accumulation in the liver, known as steatosis, without alcohol overconsumption. NAFLD can either manifest as simple steatosis or steatohepatitis, known as non-alcoholic steatohepatitis (NASH), which is accompanied by inflammation and possibly fibrosis. Furthermore, NASH might progress to hepatocellular carcinoma. NAFLD and NASH prevalence is in a continuous state of growth, and by 2018, NAFLD became a devastating m...
1 CitationsSource
Despite progress in understanding the pathophysiology of acute lung damage, currently approved treatment possibilities are limited to lung-protective ventilation, prone positioning, and supportive interventions. Various pharmacological approaches have also been tested, with neuromuscular blockers and corticosteroids considered as the most promising. However, inhibitors of phosphodiesterases (PDEs) also exert a broad spectrum of favorable effects potentially beneficial in acute lung damage. This ...
1 CitationsSource
#1Ashley Siegel (UHN: University Health Network)H-Index: 2
#2Nelson B. Rodrigues (UHN: University Health Network)H-Index: 8
Last. Joshua D. Rosenblat (U of T: University of Toronto)H-Index: 31
view all 18 authors...
Abstract Numerous pharmacological treatments for mood disorders are currently available; however, rates of treatment resistance, relapse and recurrence remain high. Therefore, novel treatments acting outside of the conventionally targeted monoamine system are urgently needed to improve patient outcomes. Emerging and converging evidence suggests that immune dysfunction, oxidative stress, impaired cerebral blood flow (CBF) and decreased neurotrophic factors all contribute to mood disorder pathophy...
#1Elsie Gyang Ross (Stanford University)H-Index: 6
Last. Matthew A. AllisonH-Index: 90
view all 3 authors...
#1Ahmed Ismaeel (FSU: Florida State University)H-Index: 6
#2Evlampia Papoutsi (FSU: Florida State University)H-Index: 7
Last. Panagiotis Koutakis (FSU: Florida State University)H-Index: 16
view all 18 authors...
Peripheral artery disease (PAD) pathophysiology extends beyond hemodynamics to include other operating mechanisms, including endothelial dysfunction. Oxidative stress may be linked to endothelial dysfunction by reducing nitric oxide (NO) bioavailability. We aimed to investigate whether the NO system and its regulators are altered in the setting of PAD and to assess the relationship between NO bioavailability and oxidative stress. Sera from 35 patients with intermittent claudication (IC), 26 pati...
2 CitationsSource
Abstract Peripheral arterial disease (PAD) is a global health problem. The risk factors for developing PAD have been clearly described in the literature, as have the medical therapies and preventative strategies for the prevention and treatment of PAD. Unfortunately, PAD patients remain undertreated with regard to guideline-directed medical therapy. During the last 2 decades, endovascular therapies for PAD have evolved such that randomized controlled trial level data are available for the treatm...
2 CitationsSource